Mirae Asset Global Investments Co. Ltd. Grows Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 25.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 374,762 shares of the company’s stock after purchasing an additional 77,186 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in AstraZeneca were worth $24,757,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. McClarren Financial Advisors Inc. increased its holdings in shares of AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in shares of AstraZeneca in the 3rd quarter worth about $28,000. Albion Financial Group UT lifted its stake in shares of AstraZeneca by 68.9% in the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after purchasing an additional 248 shares in the last quarter. Groupama Asset Managment grew its holdings in shares of AstraZeneca by 22.9% during the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after purchasing an additional 101,225 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in AstraZeneca during the 3rd quarter worth approximately $45,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

AZN opened at $70.93 on Thursday. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The firm has a market cap of $219.96 billion, a price-to-earnings ratio of 33.94, a PEG ratio of 1.18 and a beta of 0.46. The company has a fifty day simple moving average of $67.20 and a 200 day simple moving average of $73.72.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.87 earnings per share. Equities research analysts expect that AstraZeneca PLC will post 4.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.